Table 3. Multivariate Binary Logistic Regression Analyses on Factors Associated with Refractory Disease.

Parameters associated with:	All evaluable patients (n = 3,106)			B-cell subtype (n = 2,858)
	O R1	95% C.I.	p =	O R1	95% C.I	p =
Fully refractory vs responsive disease:
T-cell vs. B-cell histology	1.86	1.06–3.28	0.030	NA	NA	NA
Int/high vs. low grade histology	1.74	1.09–2.78	0.019	1.71	1.07–2.72	0.024
IPI score 3–5 vs. 0–2	4.18	2.94–5.96	<0.001	3.74	2.57–5.44	<0.001
Rituximab adm. Yes vs. No	0.43	0.30–0.62	<0.001	0.43	0.30–0.62	<0.001
HDT &autograft Yes vs. No	0.41	0.24–0.72	0.002	0.41	0.22–0.76	0.005
Gender F vs. M	0.74	0.53–1.04	0.085	0.69	0.48–0.99	0.044
LM ratio ≤2.6 vs>2.6	1.57	1.11–2.23	0.011	1.79	1.24–2.59	0.002
early progression vs responsive disease:
Int/high vs. low grade histology	1.64	0.92–2.90	0.092	1.68	0.94–3.03	0.082
IPI score 3–5 vs. 0–2	2.24	1.36–3.70	0.002	1.99	1.15–3.43	0.014
Rituximab adm. Yes vs. No	0.15	0.09–0.24	<0.001	1.16	0.10–0.27	<0.001
BM involvement Yes vs. No	2.26	1.35–3.80	0.002	2.79	1.60–4.87	<0.001
LM ratio ≤2.6 vs>2.6	1.47	0.93–2.31	0.099	1.30	0.79–2.15	0.300
HDT &autograft Yes vs. No	0.50	0.24–1.05	0.066	0.46	0.19–1.09	0.078
Gender F vs. M	0.71	0.46–1.11	0.135	0.58	0.35–0.94	0.028